Anti-RBBP9 Polyclonal Antibody for WB, IHC-P, ELISA - O75884

Core Product Specifications and Parameters

Biological Background: RBBP9 Function and Localization

• RBBP9, also known as BOG or RBBP10, is a serine hydrolase (Probable) that catalyzes the hydrolytic activation of amino acid ester prodrugs, such as converting valacyclovir to acyclovir (PubMed:32196348). Related references: PMID:32196348
• The protein negatively regulates basal or autocrine TGF-beta signaling by suppressing SMAD2-SMAD3 phosphorylation (PubMed:20080647). Related references: PMID:20080647
• RBBP9 may contribute to cellular transformation by interacting with retinoblastoma protein (RB1) and displacing E2F1 transcription factor, thereby conferring resistance to TGF-beta-mediated growth inhibition (PubMed:9697699). Related references: PMID:9697699
• It is expressed at higher levels in tumor tissues, such as carcinoma, suggesting a role in cancer progression.
• The RBBP9 gene undergoes alternative splicing, potentially generating multiple protein isoforms.
• The protein belongs to the alpha/beta hydrolase superfamily and is classified as a serine hydrolase, with a predicted molecular weight of 21 kDa.
• Its hydrolase activity and interactions with signaling proteins suggest cytoplasmic and nuclear distribution, though precise subcellular localization remains to be fully characterized.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the full-length human RBBP9 protein (amino acids 1–186); therefore, the polyclonal antibody likely recognizes multiple epitopes and may detect all splice variants.
• For Western blotting (WB), a band at approximately 21 kDa is expected; include appropriate positive and negative controls (e.g., lysates from tumor cell lines versus normal tissues) to validate specificity.
• For immunohistochemistry (IHC-P), consider heat-mediated antigen retrieval in citrate buffer (pH 6.0) to enhance signal, and validate staining in known positive carcinoma tissues.
• In ELISA applications, this antibody may be used as either capture or detection reagent; optimize coating concentration and detection system for the specific assay format.
• Cross-reactivity with mouse and rat has been reported, but protein sequence identity should be checked when designing experiments across species to account for potential epitope variations.
• Always titrate the antibody in your experimental system to determine the optimal working dilution, as performance may vary depending on sample type and detection conditions.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive sourcing partner for IVD raw materials, offering diagnostic manufacturers, laboratories, and research institutes streamlined access to high-quality antibodies like this RBBP9 polyclonal antibody. With expertise spanning the entire development pipeline—from concept to clinic—CamelBio can facilitate the procurement of validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and even rare target raw materials tailored to your specific assay needs. For researchers focused on cancer biology, TGF-beta signaling, or prodrug activation mechanisms, CamelBio provides reliable supply solutions to accelerate your diagnostic or research projects.